Treatment of Chikungunya Virus Disease in the Sub-Acute Phase
The sub-acute phase of Chikungunya virus disease is characterised by persistent symptoms that require targeted management. Clinical management during this phase is guided by the phase of the disease, and the main objective is to alleviate pain and stop the progression of inflammation.
Clinical Situation
This protocol applies to patients in the sub-acute phase of Chikungunya virus disease — those who continue to experience symptoms beyond the acute febrile period. Phase-specific management is essential, as the clinical priorities and appropriate interventions differ from those of the acute phase.
Treatment Approach (Partial Overview)
Management centres on a class of anti-inflammatory analgesics for patients with persistent symptoms, with dosing strategy adapted to address symptoms at night. Reassessment of response within the first week informs whether the approach should be adjusted.
The complete regimen — including dosing guidance, contraindication checks, and the escalation algorithm — is available in the full protocol.
References
- The clinical management of Chikungunya is based on the phase of the disease.
- The main objective of management during this phase is to alleviate pain and stop the progression of inflammation.
- NSAIDs are indicated for persistent symptoms.
- NSAIDs may be considered for the management of pain in patients with mild VAS (score 1-3) for pain.
- The NSAIDs are prescribed in full dose unless contraindicated. An evening dose or extended-release formulation can take care of night symptoms.
- The effectiveness of NSAIDs should be reassessed during the first week, and the class of NSAIDs should be changed in case of inadequate response by the 10th day.
View source ↗